# Indian pharmaceutical company financial performance

> Developing situation record from CLSTR: https://clstr.news/situations/indian-pharmaceutical-company-financial-performance
> Updated: 2026-11-07T09:11:47.000Z. Sources: 4. Developments: 2.

Major Indian pharmaceutical firms reported divergent financial results for the September quarter. Neuland Laboratories Limited experienced a 47 percent year-on-year decline in net profit and a 12.5 percent drop in revenue. Sun Pharmaceutical Industries also reported a 36.36 percent decrease in consolidated net profit, though its total revenue increased. The profit decline for Sun Pharmaceutical was attributed to exceptional charges, including a Rs 923 crore settlement for US generic-pricing antitrust litigation and costs related to the proposed acquisition of Organon.

In contrast, Gland Pharma reported a 58.29 percent increase in consolidated net profit, driven by strong execution and a 31 percent increase in its CDMO business. The company also launched four molecules in the US during this period.

## Timeline

### 2026-11-07: Indian companies Gland Pharma and Apollo Tyres report quarterly growth

Gland Pharma and Apollo Tyres reported strong quarterly results, with Gland Pharma seeing a 58 percent profit surge and Apollo Tyres achieving 17 percent revenue growth.

2 sources. https://clstr.news/cluster/indian-companies-gland-pharma-and-apollo-tyres-report-quarterly-growth

### 2026-11-02: Indian pharmaceutical companies report mixed Q2 earnings

Neuland Laboratories reported a 47 percent profit drop, while Sun Pharma saw profits fall 36 percent despite rising revenues, impacted by litigation costs and acquisition expenses.

3 sources. https://clstr.news/cluster/indian-pharmaceutical-companies-report-mixed-q2-earnings

---
Cite as: Indian pharmaceutical company financial performance. CLSTR, https://clstr.news/situations/indian-pharmaceutical-company-financial-performance